Lung Cancer Market By Type (NSCLC and SCLC), Treatment (Photodynamic therapy (PDT), Laser Therapy, Radiotherapy, Surgery and Chemotherapy) and End User (Laboratories, Hospitals & Clinics and Cancer Research Centers) - Global Industry Analysis And Forecast To 2027
Published On : September 2018 Pages : 185 Category: Pharma & Healthcare Report Code : HC091253
Industry Outlook
Lung Cancer is market is the cancer affecting the lungs, people having smoking habit are in great danger of getting affected, but also nonsmokers can also have a little risk of getting affected. Lung Cancer is the main cause for deaths in US, it is also responsible for claiming more lives that other cancers combined like prostate, ovarian, colon & breast cancer. Danger of getting affected by Lung Cancer depends on the number of cigarettes smoked & the length of smoking. Lung Cancer does not show any symptoms at initial stage, but as it advances it starts showing symptoms like; chest pain, shortness of breath, cough that is not treatable, headache, bone pain, weight loss, etc. Therefore, the Lung Cancer Market is anticipated to expand and has tremendous scope during the forecast period. The global Lung Cancer Market anticipated to flourish in the future by growing at a significantly higher CAGR.
Market Segmentation
The global Lung Cancer Market is based on segment, by Type the market is segmented into NSCLC and SCLC, by Treatment the market is segmented into Photodynamic therapy (PDT), Laser Therapy, Radiotherapy, Surgery and Chemotherapy, and by End User the market is segmented into Laboratories, Hospitals & Clinics and Cancer Research Centers.
- Lung Cancer Market, By Type
- NSCLC
- SCLC
- Lung Cancer Market, By Treatment
- Photodynamic therapy (PDT)
- Laser Therapy
- Radiotherapy
- Surgery
- Chemotherapy
- Lung Cancer Market, By End User
- Laboratories
- Hospitals & Clinics
- Cancer Research Centers
Regional Insights
On a global front, the Lung Cancer Market covers North America (United States, Canada and Mexico), Europe (Germany, UK, France, Russia, Italy, Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific), South America (Brazil, Argentina, Columbia, Rest of South America) and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA).
Lung Cancer Market, By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The leading players in the market are PFIZER INC., ELI Lilly and Company, F. Hoffmann-La Roche AG, Sanofi, BRISTOL-MYERS SQUIBB, Novartis and Merck & Co. Inc. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.
- PFIZER INC
- ELI Lilly and Company
- F. Hoffmann-La Roche AG
- Sanofi
- BRISTOL-MYERS SQUIBB
- Novartis
- Merck & Co. Inc.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
o Lung Cancer Market, By Type, Estimates and Forecast, 2017-2027 ($Million)
o NSCLC
o SCLC
o Lung Cancer Market, By Treatment, Estimates and Forecast, 2017-2027 ($Million)
o Photodynamic therapy (PDT)
o Laser Therapy
o Radiotherapy
o Surgery
o Chemotherapy
o Lung Cancer Market, By End User, Estimates and Forecast, 2017-2027 ($Million)
o Laboratories
o Hospitals & Clinics
o Cancer Research Centers
Lung Cancer Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Lung Cancer Market, By Country
o U.S. Lung Cancer Market
o Canada Lung Cancer Market
o Mexico Lung Cancer Market
o Europe
§ Europe Lung Cancer Market, By Country
o Germany Lung Cancer Market
o UK Lung Cancer Market
o France Lung Cancer Market
o Russia Lung Cancer Market
o Italy Lung Cancer Market
o Rest of Europe Lung Cancer Market
o Asia-Pacific
§ Asia-Pacific Lung Cancer Market, By Country
o China Lung Cancer Market
o Japan Lung Cancer Market
o South Korea Lung Cancer Market
o India Lung Cancer Market
o Southeast Asia Lung Cancer Market
o Rest of Asia-Pacific Lung Cancer Market
o South America
§ South America Lung Cancer Market, By Country
o Brazil Lung Cancer Market
o Argentina Lung Cancer Market
o Columbia Lung Cancer Market
o Rest of South America Lung Cancer Market
o Middle East and Africa
§ Middle East and Africa Lung Cancer Market, By Country
o Saudi Arabia Lung Cancer Market
o UAE Lung Cancer Market
o Egypt Lung Cancer Market
o Nigeria Lung Cancer Market
o South Africa Lung Cancer Market
o Rest of MEA Lung Cancer Market
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Lung Cancer Market, By Type
5.1. Introduction
5.2. Global Lung Cancer Revenue and Market Share by Type (2017-2027)
5.2.1. Global Lung Cancer Revenue and Revenue Share by Type (2017-2027)
5.3. NSCLC
5.3.1. Global NSCLC Revenue and Growth Rate (2017-2027)
5.4. SCLC
5.4.1. Global SCLC Revenue and Growth Rate (2017-2027)
6. Lung Cancer Market, By Treatment
6.1. Introduction
6.2. Global Lung Cancer Revenue and Market Share by Treatment (2017-2027)
6.2.1. Global Lung Cancer Revenue and Revenue Share by Treatment (2017-2027)
6.3. Photodynamic therapy (PDT)
6.3.1. Global Photodynamic therapy (PDT) Revenue and Growth Rate (2017-2027)
6.4. Laser Therapy
6.4.1. Global Laser Therapy Revenue and Growth Rate (2017-2027)
6.5. Radiotherapy
6.5.1. Global Radiotherapy Revenue and Growth Rate (2017-2027)
6.6. Surgery
6.6.1. Global Surgery Revenue and Growth Rate (2017-2027)
6.7. Chemotherapy
6.7.1. Global Chemotherapy Revenue and Growth Rate (2017-2027)
7. Lung Cancer Market, By End User
7.1. Introduction
7.2. Global Lung Cancer Revenue and Market Share by End User (2017-2027)
7.2.1. Global Lung Cancer Revenue and Revenue Share by End User (2017-2027)
7.3. Laboratories
7.3.1. Global Laboratories Revenue and Growth Rate (2017-2027)
7.4. Hospitals & Clinics
7.4.1. Global Hospitals & Clinics Revenue and Growth Rate (2017-2027)
7.5. Cancer Research Centers
7.5.1. Global Cancer Research Centers Revenue and Growth Rate (2017-2027)
8. Lung Cancer Market, By Region
8.1. Introduction
8.2. Global Lung Cancer Revenue and Market Share by Regions
8.2.1. Global Lung Cancer Revenue by Regions (2017-2027)
8.3. North America Lung Cancer by Countries
8.3.1. North America Lung Cancer Revenue and Growth Rate (2017-2027)
8.3.2. North America Lung Cancer Revenue (Million USD) by Countries (2017-2027)
8.3.3. United States
8.3.3.1. United States Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.4. Canada
8.3.4.1. Canada Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.5. Mexico
8.3.5.1. Mexico Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.4. Europe Lung Cancer by Countries
8.4.1. Europe Lung Cancer Revenue and Growth Rate (2017-2027)
8.4.2. Europe Lung Cancer Revenue (Million USD) by Countries (2017-2027)
8.4.3. Germany
8.4.3.1. Germany Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.4. France
8.4.4.1. France Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.5. UK
8.4.5.1. UK Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.6. Russia
8.4.6.1. Russia Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.7. Italy
8.4.7.1. Italy Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.8. Rest of Europe
8.4.8.1. Rest of Europe Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.5. Asia-Pacific Lung Cancer by Countries
8.5.1. Asia-Pacific Lung Cancer Revenue and Growth Rate (2017-2027)
8.5.2. Asia-Pacific Lung Cancer Revenue (Million USD) by Countries (2017-2027)
8.5.3. China
8.5.3.1. China Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.4. Japan
8.5.4.1. Japan Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.5. Korea
8.5.5.1. Korea Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.6. India
8.5.6.1. India Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.7. Southeast Asia
8.5.7.1. Southeast Asia Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.8. Rest of Asia-Pacific
8.5.8.1. Rest of Asia-Pacific Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.6. South America Lung Cancer by Countries
8.6.1. South America Lung Cancer Revenue and Growth Rate (2017-2027)
8.6.2. South America Lung Cancer Revenue (Million USD) by Countries (2017-2027)
8.6.3. Brazil
8.6.3.1. Brazil Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.4. Argentina
8.6.4.1. Argentina Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.5. Columbia
8.6.5.1. Columbia Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.6. Rest of South America
8.6.6.1. Rest of South America Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.7. Middle East and Africa Lung Cancer by Countries
8.7.1. Middle East and Africa Lung Cancer Revenue and Growth Rate (2017-2027)
8.7.2. Middle East and Africa Lung Cancer Revenue (Million USD) by Countries (2017-2027)
8.7.3. Saudi Arabia
8.7.3.1. Saudi Arabia Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.4. United Arab Emirates
8.7.4.1. United Arab Emirates Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.5. Egypt
8.7.5.1. Egypt Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.6. Nigeria
8.7.6.1. Nigeria Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.7. South Africa
8.7.7.1. South Africa Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.8. Turkey
8.7.8.1. Turkey Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.9. Rest of Middle East and Africa
8.7.9.1. Rest of Middle East and Africa Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
9. Company Profiles
9.1. PFIZER INC
9.1.1. Business Overview
9.1.2. Service Portfolio
9.1.3. Strategic Developments
9.1.4. Revenue and Market Share
9.2. ELI Lilly and Company
9.2.1. Business Overview
9.2.2. Service Portfolio
9.2.3. Strategic Developments
9.2.4. Revenue and Market Share
9.3. F. Hoffmann-La Roche AG
9.3.1. Business Overview
9.3.2. Service Portfolio
9.3.3. Strategic Developments
9.3.4. Revenue and Market Share
9.4. Sanofi
9.4.1. Business Overview
9.4.2. Service Portfolio
9.4.3. Strategic Developments
9.4.4. Revenue and Market Share
9.5. BRISTOL-MYERS SQUIBB
9.5.1. Business Overview
9.5.2. Service Portfolio
9.5.3. Strategic Developments
9.5.4. Revenue and Market Share
9.6. Novartis
9.6.1. Business Overview
9.6.2. Service Portfolio
9.6.3. Strategic Developments
9.6.4. Revenue and Market Share
9.7. Merck & Co. Inc.
9.7.1. Business Overview
9.7.2. Service Portfolio
9.7.3. Strategic Developments
9.7.4. Revenue and Market Share
10. Global Lung Cancer Market Competition, by Manufacturer
10.1. Global Lung Cancer Revenue and Market Share by Manufacturer (2017-2017)
10.2. Global Lung Cancer Price By Region (2017-2017)
10.3. Top 5 Lung Cancer Manufacturer Market Share
10.4. Market Competition Trend
11. Lung Cancer Market Forecast (2017-2027)
11.1. Global Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
11.2. Lung Cancer Market Forecast by Regions (2017-2027)
11.2.1. North America Lung Cancer Market Forecast (2017-2027)
11.2.1.1. United States Lung Cancer Market Forecast (2017-2027)
11.2.1.2. Canada Lung Cancer Market Forecast (2017-2027)
11.2.1.3. Mexico Lung Cancer Market Forecast (2017-2027)
11.2.2. Europe Lung Cancer Market Forecast (2017-2027)
11.2.2.1. Germany Lung Cancer Market Forecast (2017-2027)
11.2.2.2. France Lung Cancer Market Forecast (2017-2027)
11.2.2.3. UK Lung Cancer Market Forecast (2017-2027)
11.2.2.4. Russia Lung Cancer Market Forecast (2017-2027)
11.2.2.5. Italy Lung Cancer Market Forecast (2017-2027)
11.2.2.6. Rest of Europe Lung Cancer Market Forecast (2017-2027)
11.2.3. Asia-Pacific Lung Cancer Market Forecast (2017-2027)
11.2.3.1. China Lung Cancer Market Forecast (2017-2027)
11.2.3.2. Japan Lung Cancer Market Forecast (2017-2027)
11.2.3.3. Korea Lung Cancer Market Forecast (2017-2027)
11.2.3.4. India Lung Cancer Market Forecast (2017-2027)
11.2.3.5. Southeast Asia Lung Cancer Market Forecast (2017-2027)
11.2.3.6. Rest of Asia-Pacific Lung Cancer Market Forecast (2017-2027)
11.2.4. South America Lung Cancer Market Forecast (2017-2027)
11.2.4.1. Brazil Lung Cancer Market Forecast (2017-2027)
11.2.4.2. Argentina Lung Cancer Market Forecast (2017-2027)
11.2.4.3. Columbia Lung Cancer Market Forecast (2017-2027)
11.2.4.4. Rest of South America Lung Cancer Market Forecast (2017-2027)
11.2.5. Middle East and Africa Lung Cancer Market Forecast (2017-2027)
11.2.5.1. Saudi Arabia Lung Cancer Market Forecast (2017-2027)
11.2.5.2. United Arab Emirates Lung Cancer Market Forecast (2017-2027)
11.2.5.3. Egypt Lung Cancer Market Forecast (2017-2027)
11.2.5.4. Nigeria Lung Cancer Market Forecast (2017-2027)
11.2.5.5. South Africa Lung Cancer Market Forecast (2017-2027)
11.2.5.6. Turkey Lung Cancer Market Forecast (2017-2027)
11.2.5.7. Rest of Middle East and Africa Lung Cancer Market Forecast (2017-2027)
11.3. Lung Cancer Market Forecast by Type (2017-2027)
11.3.1. Lung Cancer Forecast by Type (2017-2027)
11.3.2. Lung Cancer Market Share Forecast by Type (2017-2027)
11.4. Lung Cancer Market Forecast by Treatment (2017-2027)
11.4.1. Lung Cancer Forecast by Treatment (2017-2027)
11.4.2. Lung Cancer Market Share Forecast by Treatment (2017-2027)
11.5. Lung Cancer Market Forecast by End User (2017-2027)
11.5.1. Lung Cancer Forecast by End User (2017-2027)
11.5.2. Lung Cancer Market Share Forecast by End User (2017-2027)
List of Tables
12. List of Tables and Figures
Figure United States Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Lung Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Lung Cancer Revenue and Revenue Share by Type (2017-2018)
Figure Global NSCLC Revenue and Growth Rate (2017-2018)
Figure Global SCLC Revenue and Growth Rate (2017-2018)
Table Global Lung Cancer Revenue and Revenue Share by Treatment (2017-2018)
Figure Global Photodynamic therapy (PDT) Revenue and Growth Rate (2017-2018)
Figure Global Laser Therapy Revenue and Growth Rate (2017-2018)
Figure Global Radiotherapy Revenue and Growth Rate (2017-2018)
Figure Global Surgery Revenue and Growth Rate (2017-2018)
Figure Global Chemotherapy Revenue and Growth Rate (2017-2018)
Table Global Lung Cancer Revenue and Revenue Share by End User (2017-2018)
Figure Global Laboratories Revenue and Growth Rate (2017-2018)
Figure Global Hospitals & Clinics Revenue and Growth Rate (2017-2018)
Figure Global Cancer Research Centers Revenue and Growth Rate (2017-2018)
Table Global Lung Cancer Revenue by Regions (2017-2018)
Figure North America Lung Cancer Growth Rate (2017-2018)
Figure North America Lung Cancer Revenue and Growth Rate (2017-2018)
Figure North America Lung Cancer by Countries (2017-2018)
Figure North America Lung Cancer Revenue (Million USD) by Countries (2017-2018)
Figure United States Lung Cancer Growth Rate (2017-2018)
Figure United States Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Lung Cancer Growth Rate (2017-2018)
Figure Canada Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Lung Cancer Growth Rate (2017-2018)
Figure Mexico Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Lung Cancer Growth Rate (2017-2018)
Figure Europe Lung Cancer Revenue and Growth Rate (2017-2018)
Figure Europe Lung Cancer by Countries (2017-2018)
Figure Europe Lung Cancer Revenue (Million USD) by Countries (2017-2018)
Figure Germany Lung Cancer Growth Rate (2017-2018)
Figure Germany Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Lung Cancer Growth Rate (2017-2018)
Figure France Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Lung Cancer Growth Rate (2017-2018)
Figure UK Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Lung Cancer Growth Rate (2017-2018)
Figure Russia Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Lung Cancer Growth Rate (2017-2018)
Figure Italy Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Lung Cancer Growth Rate (2017-2018)
Figure Rest of Europe Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Lung Cancer Growth Rate (2017-2018)
Figure Asia-Pacific Lung Cancer Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Lung Cancer by Countries (2017-2018)
Figure Asia-Pacific Lung Cancer Revenue (Million USD) by Countries (2017-2018)
Figure China Lung Cancer Growth Rate (2017-2018)
Figure China Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Lung Cancer Growth Rate (2017-2018)
Figure Japan Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Lung Cancer Growth Rate (2017-2018)
Figure Korea Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Lung Cancer Growth Rate (2017-2018)
Figure India Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Lung Cancer Growth Rate (2017-2018)
Figure Southeast Asia Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Lung Cancer Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Lung Cancer Growth Rate (2017-2018)
Figure South America Lung Cancer Revenue and Growth Rate (2017-2018)
Figure South America Lung Cancer by Countries (2017-2018)
Figure South America Lung Cancer Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Lung Cancer Growth Rate (2017-2018)
Figure Brazil Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Lung Cancer Growth Rate (2017-2018)
Figure Argentina Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Lung Cancer Growth Rate (2017-2018)
Figure Columbia Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Lung Cancer Growth Rate (2017-2018)
Figure Rest of South America Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Lung Cancer Growth Rate (2017-2018)
Figure Middle East and Africa Lung Cancer Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Lung Cancer by Countries (2017-2018)
Figure Middle East and Africa Lung Cancer Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Lung Cancer Growth Rate (2017-2018)
Figure Saudi Arabia Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Lung Cancer Growth Rate (2017-2018)
Figure United Arab Emirates Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Lung Cancer Growth Rate (2017-2018)
Figure Egypt Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Lung Cancer Growth Rate (2017-2018)
Figure Nigeria Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Lung Cancer Growth Rate (2017-2018)
Figure South Africa Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Lung Cancer Growth Rate (2017-2018)
Figure Turkey Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Lung Cancer Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Lung Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Table PFIZER INC Lung Cancer Price, Revenue, Gross Margin and Market Share (2017-2017)
Table ELI Lilly and Company Lung Cancer Price, Revenue, Gross Margin and Market Share (2017-2017)
Table F. Hoffmann-La Roche AG Lung Cancer Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Sanofi Lung Cancer Price, Revenue, Gross Margin and Market Share (2017-2017)
Table BRISTOL-MYERS SQUIBB Lung Cancer Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Novartis Lung Cancer Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Merck & Co. Inc. Lung Cancer Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Lung Cancer Market Share by Manufacturer
Figure Global Lung Cancer Revenue and Market Share by Manufacturer
Table Global Lung Cancer Price by Region (2017-2017)
Figure Top 5 Lung Cancer Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Lung Cancer Revenue (Millions USD) and Growth Rate (2018-2025)
Table Lung Cancer Market Forecast by Regions (2018-2025)
Figure North America Lung Cancer Market Forecast (2018-2025)
Figure United States Lung Cancer Market Forecast (2018-2025)
Figure Canada Lung Cancer Market Forecast (2018-2025)
Figure Mexico Lung Cancer Market Forecast (2018-2025)
Figure Europe Lung Cancer Market Forecast (2018-2025)
Figure Germany Lung Cancer Market Forecast (2018-2025)
Figure France Lung Cancer Market Forecast (2018-2025)
Figure UK Lung Cancer Market Forecast (2018-2025)
Figure Russia Lung Cancer Market Forecast (2018-2025)
Figure Italy Lung Cancer Market Forecast (2018-2025)
Figure Rest of Europe Lung Cancer Market Forecast (2018-2025)
Figure Asia-Pacific Lung Cancer Market Forecast (2018-2025)
Figure China Lung Cancer Market Forecast (2018-2025)
Figure Japan Lung Cancer Market Forecast (2018-2025)
Figure Korea Lung Cancer Market Forecast (2018-2025)
Figure India Lung Cancer Market Forecast (2018-2025)
Figure Southeast Asia Lung Cancer Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Lung Cancer Market Forecast (2018-2025)
Figure South America Lung Cancer Market Forecast (2018-2025)
Figure Brazil Lung Cancer Market Forecast (2018-2025)
Figure Argentina Lung Cancer Market Forecast (2018-2025)
Figure Columbia Lung Cancer Market Forecast (2018-2025)
Figure Rest of South America Lung Cancer Market Forecast (2018-2025)
Figure Middle East and Africa Lung Cancer Market Forecast (2018-2025)
Figure Saudi Arabia Lung Cancer Market Forecast (2018-2025)
Figure United Arab Emirates Lung Cancer Market Forecast (2018-2025)
Figure Egypt Lung Cancer Market Forecast (2018-2025)
Figure Nigeria Lung Cancer Market Forecast (2018-2025)
Figure South Africa Lung Cancer Market Forecast (2018-2025)
Figure Turkey Lung Cancer Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Lung Cancer Market Forecast (2018-2025)
Figure Global Lung Cancer Forecast by Type (2018-2025)
Figure Global Lung Cancer Market Share Forecast by Type (2018-2025)
Figure Global Lung Cancer Forecast by Type (2018-2025)
Figure Global Lung Cancer Forecast by Treatment (2018-2025)
Figure Global Lung Cancer Market Share Forecast by Treatment (2018-2025)
Figure Global Lung Cancer Forecast by Treatment (2018-2025)
Figure Global Lung Cancer Forecast by End User (2018-2025)
Figure Global Lung Cancer Market Share Forecast by End User (2018-2025)
Figure Global Lung Cancer Forecast by End User (2018-2025)
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|